Results 71 to 80 of about 45,905 (256)

A survey on concomitant common bile duct stone and symptomatic gallstone and clinical values in Shiraz, Southern Iran

open access: yesAdvanced Biomedical Research, 2016
Background: Common bile duct stone (CBDS) as a result of gallstone is one of the gastrointestinal disorders. In this study, the incidence of CBDS and symptomatic gallstone in Shiraz were investigated, and their management suggested. Materials and Methods:
Seyed Vahid Hosseini   +6 more
doaj   +1 more source

Defining Age to Screen and Real‐World Effectiveness for Early‐Onset Colorectal Cancer

open access: yesCancer Science, EarlyView.
Implementation of a RAP‐based risk‐adapted screening strategy enables personalized screening initiation, with benefits comparable to those observed in the current 50–54‐year age group.
Le Wang   +8 more
wiley   +1 more source

Gallstone formation: Local factors

open access: yes, 1999
Supersaturation of bile is a necessary prerequisite to gallstone formation. However, patients who have undergone a cholecystectomy do not form gallstones. This indicates a role of local factors in gallstone formation. Gallbladder stasis, mucin secretion,
Ko, CW, Lee, SP
core   +1 more source

Management of Gallstone

open access: yesThe Korean Journal of Gastroenterology, 2018
Gallstones are one of the most common diseases worldwide. Recently, the incidence of gallstones has increased and the pattern of gallstones has changed in Korea. Laparoscopic cholecystectomy is the standard treatment for symptomatic gallstones. Expectant management is considered the most appropriate choice in patients with asymptomatic gallstones.
openaire   +3 more sources

Incretin‐Based Therapies as Cardiometabolic Interventions: Outcome Hierarchy, Receptor‐Network Pharmacology and Phenotype‐Based Clinical Positioning

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Incretin‐based pharmacotherapy was initially developed to improve glucose‐dependent insulin secretion and glycaemic control in type 2 diabetes, but its clinical interpretation has expanded substantially with cardiovascular outcome trials, kidney outcome data, obesity studies and next‐generation polyagonist development.
Ferenc Sztanek   +3 more
wiley   +1 more source

Hepatic cholesterol metabolism in cholesterol gallstone disease

open access: yesJournal of Lipid Research, 1991
Hepatic cholesterol metabolism was examined in 27 Swedish patients with cholesterol gallstone disease and in 13 patients free of gallstones operated for roentgenographically suspect polyps in the gallbladder.
E Reihnér   +3 more
doaj   +1 more source

Biliary Abnormality on Imaging During Lenvatinib Plus Hepatic Arterial Infusion Chemotherapy With Cisplatin for Hepatocellular Carcinoma: A Pilot Descriptive Study

open access: yesHepatology Research, EarlyView.
ABSTRACT Aim To evaluate the frequency, imaging characteristics, associated factors, and clinical significance of biliary abnormalities on imaging in patients receiving lenvatinib (LEN) plus cisplatin hepatic arterial infusion chemotherapy (HAIC) for hepatocellular carcinoma (HCC).
Hirohito Osanai   +10 more
wiley   +1 more source

Gallstone Ileus Caused by Migration of Gallstone Through Cholecystoduodenal Fistula Resulting in Small Bowel Obstruction

open access: yes, 2023
Gallstone ileus is a rare condition characterized by mechanical obstruction of the intestine due to gallstone impaction. Diagnosis is based on clinical history, symptoms, and characteristic Computed Tomography (CT) scan findings.
Zackria, Rasiq   +4 more
core   +1 more source

siRNA/CS‐PLGA Nanoparticle System Targeting Knockdown Intestinal SOAT2 Reduced Intestinal Lipid Uptake and Alleviated Obesity

open access: yesAdvanced Science
Effective inhibition of intestinal lipid uptake is an efficient strategy for the treatment of disorders related to lipid metabolism. Sterol O‐acyltransferase 2 (SOAT2) is responsible for the esterification of free cholesterol and fatty acids into ...
Jingjia Liang   +12 more
doaj   +1 more source

Adaptations of glucagon‐like peptide‐1 receptor agonist‐induced weight loss, drivers of weight regain and future directions of therapeutics

open access: yesThe Journal of Physiology, EarlyView.
Abstract figure legend During GLP‐1RA treatment reduced appetite and energy intake, delayed gastric emptying, decreased visceral fat mass and improved glycaemic control contribute to weight loss. After treatment cessation these benefits are partially or completely reversed, resulting in weight regain, accompanied by increased appetite and energy intake,
Camille E. M. Piguet   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy